Dopaminergic mechanisms in patients with extrapyramidal disease.
D000818:Animals; D001679:Biogenic Amines / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D002110:Caffeine / Q000008:administration & dosage; D003000:Clonidine / Q000009:adverse effects; D004298:Dopamine; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007980:Levodopa / Q000627:therapeutic use; D010276:Parasympatholytics / Q000008:administration & dosage; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D010891:Piribedil / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D051381:Rats; D011955:Receptors, Drug; D013268:Stimulation, Chemical
D001679:Biogenic Amines; D010276:Parasympatholytics; D010879:Piperazines; D011955:Receptors, Drug; D002110:Caffeine; D007980:Levodopa; D006897:Hydroxyindoleacetic Acid; D011388:Prolactin; D010891:Piribedil; D003000:Clonidine; D004298:Dopamine; D006719:Homovanillic Acid